Press Release Source: Patheon Inc.; Solvias AG
Friday November 14, 7:30 am ET
Website: www.patheon.com TORONTO, Nov. 14 /CNW/ - Patheon (TSX:PTI), and Solvias AG, are pleased to announce a global alliance to offer integrated development services to pharmaceutical and biotechnology companies. This alliance combines Patheon's experience and expertise in formulation development with Solvias AG's reputation of excellence in pre-formulation and solid state chemistry.
The partnering of Patheon and Solvias AG will provide customers flexible and integrated early development services including API characterization, salt selection and co-crystallization, polymorphism screening, solubility determination, excipient compatibility and formulation. Patheon's innovative Quick to Clinic(SM) program will be implemented for rapid Phase I development and to optimize programs for special molecules such as those with low solubility or challenging solid-state properties.
Wes Wheeler, Chief Executive Officer and President, stated, "Patheon's vision is to be the best provider of services. This alliance with Solvias is an example of how Patheon is committed to providing and expanding these turnkey solutions for the most integrated, value added service offering for our customers."
"For Solvias, the alliance with Patheon is an ideal fit with our existing integrated approach to the development of drug substances, as it expands the range of services we can offer our customers to now include formulation of APIs for early clinical phases. We believe that the ability to provide fully integrated chemical development services from early stage drug development through formulation is a clear benefit to our customers as it will result in greater efficiencies, reduced interfaces, and better information flow, therefore their development timelines will be significantly accelerated", said Phillip M. Chalabi, Vice President of Business Development at Solvias.
ABOUT PATHEON
Patheon Inc. (TSX: PTI; www.patheon.com) is a leading provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon provides products and services to more than three hundred of the world's leading pharmaceutical and biotechnical companies. Patheon's technologies and services range from pre-clinical development to manufacturing a full array of dosage forms. Their global network of ten manufacturing facilities and seven development centers ensures that customer products can be launched with confidence anywhere in the world.
ABOUT SOLVIAS
Solvias AG (www.solvias.com) is a privately held company located in Basel (Switzerland). With 280 highly qualified employees it supports the research and development of new drug substances and the optimization of manufacturing processes for pharmaceutical and biotechnology companies worldwide. Solvias' customers benefit from a wide range of experience in polymorphism screening, salt selection, catalysis, asymmetric synthesis, custom synthesis, process R&D, and analytical services.
Caution Concerning Forward-Looking Statements
This news release may contain forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities. These statements are made in the context of the risks and uncertainties that are outlined in the Company's public documents, which can be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.
For further information
Mr. Wes Wheeler, President & Chief Executive Officer, Tel: (905) 812-2112, Email: wes.wheeler@patheon.com Mr. Eric Evans, Chief Financial Officer, Tel: (905) 812-6660, Email: eric.evans@patheon.com Ms. Jean Treadwell, Investor Relations, Tel: (905) 816-8344, Email: jean.treadwell@patheon.com Solvias Media Relations, Solvias AG, Dr. Peter Loew, P.O. Box 4002 Basel (Switzerland), Tel. +41 61 686 61 63, Fax +41 61 686 61 00, E-Mail info@solvias.com
Source: Patheon Inc.; Solvias AG